DORA PSI | Digital Object Repository at PSI

Export As:

Style

Style

Search Results 1 - 6 of 6

Sort

	Select Page
	Relaxed fibronectin: a potential novel target for imaging endometriotic lesions Trachsel, B., Imobersteg, S., Valpreda, G., Singer, G., Grabherr, R., Ormos, M., … Béhé, M. (2024). Relaxed fibronectin: a potential novel target for imaging endometriotic lesions. EJNMMI Research, 14(1), 17 (11 pp.). https://doi.org/10.1186/s13550-024-01070-0 Detailed Record Published Version
	Signaling network response to <em>α</em>-particle–targeted therapy with the <sup>225</sup>Ac-labeled minigastrin analog <sup>225</sup>Ac-PP-F11N reveals the radiosensitizing potential of histone deacetylase inhibitors Qin, Y., Imobersteg, S., Frank, S., Blanc, A., Chiorazzo, T., Berger, P., … Grzmil, M. (2023). Signaling network response to α-particle–targeted therapy with the ²²⁵Ac-labeled minigastrin analog ²²⁵Ac-PP-F11N reveals the radiosensitizing potential of histone deacetylase inhibitors. Journal of Nuclear Medicine, 64(6), 873-879. https://doi.org/10.2967/jnumed.122.264597 Detailed Record Published Version
	Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT) Grzmil, M., Boersema, P., Sharma, A., Blanc, A., Imobersteg, S., Pruschy, M., … Behe, M. (2022). Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT). Journal of Hematology & Oncology, 15(1), 123 (5 pp.). https://doi.org/10.1186/s13045-022-01343-y Detailed Record Published Version
	Therapeutic response of CCKBR-positive tumors to combinatory treatment with everolimus and the radiolabeled minigastrin analogue [<sup>177</sup>Lu]Lu-PP-F11N Grzmil, M., Imobersteg, S., Blanc, A., Frank, S., Schibli, R., & Béhé, M. P. (2021). Therapeutic response of CCKBR-positive tumors to combinatory treatment with everolimus and the radiolabeled minigastrin analogue [¹⁷⁷Lu]Lu-PP-F11N. Pharmaceutics, 13(12), 2156 (8 pp.). https://doi.org/10.3390/pharmaceutics13122156 Detailed Record Published Version
	Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [<sup>177</sup>Lu]Lu-PP-F11N Grzmil, M., Qin, Y., Schleuniger, C., Frank, S., Imobersteg, S., Blanc, A., … Behe, M. (2020). Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [¹⁷⁷Lu]Lu-PP-F11N. Theranostics, 10(24), 10861-10873. https://doi.org/10.7150/thno.45440 Detailed Record Published Version
	Evaluation of actinium-225 labeled minigastrin analogue [<sup>225</sup>Ac]Ac-DOTA-PP-F11N for targeted alpha particle therapy Qin, Y., Imobersteg, S., Blanc, A., Frank, S., Schibli, R., Béhé, M. P., & Grzmil, M. (2020). Evaluation of actinium-225 labeled minigastrin analogue [²²⁵Ac]Ac-DOTA-PP-F11N for targeted alpha particle therapy. Pharmaceutics, 12(11), 1088 (12 pp.). https://doi.org/10.3390/pharmaceutics12111088 Detailed Record Published Version